Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations.
Deborah B DoroshowPeter H O'DonnellJean H Hoffman-CensitsSumati V GuptaUlka N VaishampayanElisabeth I HeathPhilip GarciaQianqian ZhaoMenggang YuMatthew I MilowskyMatthew D GalskyPublished in: JCO precision oncology (2023)
Single-agent olaparib showed limited antitumor activity in patients with mUC and DDR alterations, which may be related to poorly characterized functional implications of particular DDR alterations and/or cross-resistance with platinum-based chemotherapy in a disease where such therapy represents standard first-line treatment.